Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Part, First-in-human, Double-Blind, Randomized, and Placebo-Controlled Study Assessing the Safety, Tolerability, and Efficacy of TO-O-1001 Ophthalmic Solution in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

Next Previous
Trial Profile

A 3-Part, First-in-human, Double-Blind, Randomized, and Placebo-Controlled Study Assessing the Safety, Tolerability, and Efficacy of TO-O-1001 Ophthalmic Solution in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TO O 1001 (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Theratocular Biotek

Most Recent Events

  • 22 Mar 2023 Status changed from not yet recruiting to active, no longer recruiting.
  • 22 Mar 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2024.
  • 22 Mar 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top